TRT(600085) 证券日报网·2025-03-29 03:49Core Viewpoint - Tongrentang Technology reported a revenue of 7.26 billion and a net profit of 0.887 billion for the fiscal year 2024, demonstrating resilience in a challenging pharmaceutical market environment [1] Group 1: Financial Performance - The company achieved a revenue of 7.26 billion and a net profit of 0.887 billion during the reporting period [1] - Despite challenges such as rising raw material prices and decreased foot traffic in stores, the company improved its overall operational quality [1] Group 2: Innovation and R&D - Tongrentang Technology increased its investment in research and development, accelerating the development of innovative drugs and classic formulas [2] - The company received clinical trial approval for Qishen Granules, marking its first clinical approval for a traditional Chinese medicine in eight years [2] - Several products underwent pharmacological mechanism studies, enhancing their market competitiveness and clinical recognition [2] Group 3: Market Strategy and Product Expansion - In response to external challenges, the company adjusted its market strategy, focusing on channel management, price stability, and terminal empowerment [3] - The company launched promotional activities for its "Yuyao 300" product line, resulting in nine products exceeding 0.1 billion in sales [3] Group 4: Channel Development - Tongrentang Technology strengthened its partnerships with major distributors and conducted over 450 promotional events in previously untapped markets [4] - The company aimed to enhance product distribution rates and terminal effectiveness through targeted market strategies [4] Group 5: Risk Management and Future Plans - The company plans to enhance its governance and core competitiveness to address risks and challenges [5] - Future initiatives include a new round of collaborative innovation in traditional Chinese medicine, aiming to complete clinical research on five products by 2025 [5]